Disseminated Kaposi sarcoma following COVID-19 in a 61-year-old Albanian immunocompetent man: a case report and review of the literature.
COVID-19
HHV-8
Kaposi sarcoma
Latent infection
Reactivation
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
20 Dec 2021
20 Dec 2021
Historique:
received:
02
09
2021
accepted:
08
12
2021
entrez:
21
12
2021
pubmed:
22
12
2021
medline:
31
12
2021
Statut:
epublish
Résumé
COVID-19 and its related anti-inflammatory treatment (steroids, immunomodulators) may induce the reactivation of latent bacterial, parasitic, and viral infections. According to our knowledge, no case of disseminated HHV-8-related Kaposi sarcoma (KS) after COVID-19 and its treatment has been described so far. Only one case of cutaneous KS concurrently with COVID-19 has been previously reported. We describe a case of disseminated KS in a 61-year-old immunocompetent Albanian man after hospitalization for COVID-19. We used PubMed as biomedical database for the literature research. We selected keyword combinations including "Kaposi sarcoma," "HHV-8," "immunocompetent," "COVID-19," "SARS-CoV-2," and "steroids." No time or language limitation was set. Titles and abstracts of selected articles were systematically screened. Articles were included in the examination if they were published under free access through the digital library of the University of Brescia (Italy), and provided full text. Articles were excluded if the topic was beyond the aim of our study. Finally, we selected 15 articles. We describe a case of KS in COVID-19 patient and postulate that Interleukin-6 (IL-6) activity and steroid-induced immunodeficiency may play a major role in KS emergence. No published case of disseminated KS following COVID-19 in otherwise healthy individuals was found through the systematic literature review, despite the high incidence of COVID-19 in areas with medium-high prevalence of HHV-8 infection. This observation might be explained by the role of individual genetic susceptibility factors. SARS-CoV-2 infection and its treatment may lead to reactivation of several latent infections, including HHV-8 and its related clinical syndrome, Kaposi sarcoma.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 and its related anti-inflammatory treatment (steroids, immunomodulators) may induce the reactivation of latent bacterial, parasitic, and viral infections. According to our knowledge, no case of disseminated HHV-8-related Kaposi sarcoma (KS) after COVID-19 and its treatment has been described so far. Only one case of cutaneous KS concurrently with COVID-19 has been previously reported.
CASE PRESENTATION
METHODS
We describe a case of disseminated KS in a 61-year-old immunocompetent Albanian man after hospitalization for COVID-19.
METHODS FOR LITERATURE RESEARCH
UNASSIGNED
We used PubMed as biomedical database for the literature research. We selected keyword combinations including "Kaposi sarcoma," "HHV-8," "immunocompetent," "COVID-19," "SARS-CoV-2," and "steroids." No time or language limitation was set. Titles and abstracts of selected articles were systematically screened. Articles were included in the examination if they were published under free access through the digital library of the University of Brescia (Italy), and provided full text. Articles were excluded if the topic was beyond the aim of our study. Finally, we selected 15 articles.
RESULTS
RESULTS
We describe a case of KS in COVID-19 patient and postulate that Interleukin-6 (IL-6) activity and steroid-induced immunodeficiency may play a major role in KS emergence. No published case of disseminated KS following COVID-19 in otherwise healthy individuals was found through the systematic literature review, despite the high incidence of COVID-19 in areas with medium-high prevalence of HHV-8 infection. This observation might be explained by the role of individual genetic susceptibility factors.
CONCLUSIONS
CONCLUSIONS
SARS-CoV-2 infection and its treatment may lead to reactivation of several latent infections, including HHV-8 and its related clinical syndrome, Kaposi sarcoma.
Identifiants
pubmed: 34930492
doi: 10.1186/s40001-021-00620-9
pii: 10.1186/s40001-021-00620-9
pmc: PMC8686807
doi:
Substances chimiques
Interleukin-6
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
152Informations de copyright
© 2021. The Author(s).
Références
New Microbiol. 2003 Jan;26(1):1-6
pubmed: 12578305
Clin Rheumatol. 2007 Mar;26(3):440-2
pubmed: 16437363
Cancer. 1993 Sep 1;72(5):1779-83
pubmed: 8348508
Clin Exp Dermatol. 2017 Aug;42(6):702-704
pubmed: 28598021
JAAD Case Rep. 2017 Sep 03;3(5):441-443
pubmed: 28913409
J Korean Med Sci. 2009 Oct;24(5):970-4
pubmed: 19795003
Commun Biol. 2021 Jun 3;4(1):682
pubmed: 34083759
J Dermatol Case Rep. 2012 Mar 27;6(1):8-13
pubmed: 22514583
J Med Virol. 2021 Apr;93(4):1850-1851
pubmed: 32970319
Rev Med Virol. 2020 Nov;30(6):1-9
pubmed: 32845568
Br J Dermatol. 2020 Dec;183(6):1145-1147
pubmed: 32790074
J Eur Acad Dermatol Venereol. 2021 May;35(5):e311-e312
pubmed: 33460479
Am J Surg Pathol. 2006 Jan;30(1):123-7
pubmed: 16330952
Dermatol Online J. 2015 Oct 16;21(10):
pubmed: 26632797
Int J STD AIDS. 2021 May;32(6):582-584
pubmed: 33533293
Int J Dermatol. 2020 Aug;59(8):1028-1029
pubmed: 32530063
Int J Surg Pathol. 2018 May;26(3):276-282
pubmed: 29169276
Eur J Epidemiol. 2004;19(5):467-9
pubmed: 15233320
J Viral Hepat. 2021 Jan;28(1):89-94
pubmed: 32969557
Clin Exp Dermatol. 2005 Jul;30(4):395-7
pubmed: 15953080
Ann Otol Rhinol Laryngol. 2008 Mar;117(3):172-6
pubmed: 18444476
Infection. 2021 Jun;49(3):539-542
pubmed: 32910321
Eur J Haematol. 2007 Apr;78(4):361-4
pubmed: 17331129
Eur J Case Rep Intern Med. 2016 Sep 19;3(7):000493
pubmed: 30755897